乳腺癌组织中miR-491-5p ZNF703的表达变化及与预后关系

doi:10.3969/j.issn.1006-6233.2025.09.018

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1452 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the expression changes of microRNA-491-5p (miR-491-5p) and zinc finger protein 703 (ZNF703) in breast cancer tissues and their relationship with prognosis. Methods: A total of 153 breast cancer patients (breast cancer group) who underwent surgical resection in our hospital from January 2017 to August 2019, and 153 patients with benign breast tumors who underwent benign breast lesion resection during the same period (control group), were included. Real-time quantitative polymerase chain reaction was used to detect the expression of miR-491-5p and ZNF703 mRNA in breast cancer and benign lesion tissues. Online databases were used to predict the binding sites between miR-491-5p and ZNF703, and the correlation between miR-491-5p and ZNF703 mRNA expression in breast cancer tissues was analyzed using Pearson correlation analysis. Based on the average expression levels of miR-491-5p and ZNF703 mRNA in breast cancer tissue, patients were divided into high-expression and low-expression groups. Kaplan-Meier survival curves were plotted for breast cancer patients with different miR-491-5p and ZNF703 expression levels, and multivariate Cox regression analysis was performed to examine the relationship between miR-491-5p and ZNF703 mRNA expression and patient prognosis. Results: Compared with the control group, miR-491-5p was under-expressed, while ZNF703 mRNA was over-expressed in the breast cancer group (P<0.05). A binding site was identified at the 3'-untranslated region (127-133) of ZNF703 for miR-491-5p, and the two showed a negative correlation in breast cancer tissues (P<0.05). Breast cancer tissues with a tumor diameter ≥2 cm, low differentiation, TNM stage Ⅲ-Ⅳ, lymph node metastasis, or distant metastasis showed lower miR-491-5p expression and higher ZNF703 mRNA expression compared to those with a tumor diameter <2 cm, medium/high differentiation, TNM stage Ⅰ-Ⅱ, no lymph node metastasis, or no distant metastasis (P<0.05). The 5-year overall survival rate of 153 breast cancer patients was 77.12% (118/153). Patients with high miR-491-5p expression had a higher 5-year survival rate than those with low miR-491-5p expression, while those with high ZNF703 mRNA expression had a lower survival rate compared to patients with low ZNF703 mRNA expression (P<0.05). Multivariate Cox regression analysis showed miR-491-5p ≥0.86 was identified as an independent protective factor, while ZNF703 mRNA ≥1.46 was an independent risk factor for breast cancer patient mortality (P<0.05). Conclusion: miR-491-5p is under-expressed and ZNF703 mRNA is over-expressed in breast cancer tissues, which are associated with poor pathological features and prognosis. They may serve as novel biomarkers for evaluating breast cancer prognosis.

Key words： Breast cancer MicroRNA-491-5p Zinc finger protein 703

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHOU Aiping
	YANG Fan
	WU Landi
	et al

Cite this article:

ZHOU Aiping,YANG Fan,WU Landi, et al. Expression Changes of miR-491-5p and ZNF703 in Breast Cancer Tissues and The Relationship with Prognosis[J]. HeBei Med, 2025, 31(9): 1514-1520.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2025.09.018 OR http://www.hbyxzzs.cn/EN/Y2025/V31/I9/1514

[1] 郑荣寿,陈茹,韩冰峰,等.2022年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2024,46(3):221-231.
[2] Panvongsa W,Siripoon T,Worakitchanon W,et al.Plasma extracellular vesicle microRNA-491-5p as diagnostic and prognostic marker for head and neck squamous cell carcinoma[J].Cancer Sci,2021,112(10):4257-4269.
[3] Wang S,Liu R.Insights into the pleiotropic roles of ZNF703 in cancer[J].Heliyon,2023,9(9):20140.
[4] Mohamed AH,Harb OA,Shorbagy SE,et al.Prognostic roles of ZNF703 and SMAD4 expression in patients with papillary thyroid cancer and association with nodal metastasis[J].Indian Surg Oncol,2022,13(1):169-177.
[5] 国家肿瘤质控中心乳腺癌专家委员会,中国抗癌协会乳腺癌专业委员会,中国抗癌协会肿瘤药物临床研究专业委员会.中国晚期乳腺癌规范诊疗指南(2024版)[J].中华肿瘤杂志,2024,46(12):1079-1106.
[6] 雷志鑫,杨海旖,谢浩,等.miRNA在乳腺癌中的研究进展[J].华中农业大学学报,2024,43(5):149-156.
[7] Wang D,Zhang S,Wang Q,et al.Circ_0001741 exerts as a tumor promoter in ovarian cancer through the regulation of miR-491-5p/PRSS8 axis[J].Discov Oncol,2024,15(1):643..
[8] Zhang LX,Luo PQ,Wei ZJ,et al.Expression and significant roles of the long non-coding RNA CASC19/miR-491-5p/HMGA2 axis in the development of gastric cancer[J].World Gastrointest Oncol,2024,16(8):3559-3584.
[9] 朱超,张立功,郭晨旭,等.miR-491-5p靶向FOLR1对乳腺癌细胞增殖及侵袭的影响[J].山西医科大学学报,2023,54(10):1338-1346.
[10] Huang WC,Chi HC,Tung SL,et al.Identification of the novel tumor suppressor role of FOCAD/miR-491-5p to inhibit cancer stemness,drug resistance and metastasis via regulating RABIF/MMP signaling in triple negative breast cancer[J].Cells,2024,13(22):1830.
[11] Wang F,Li Y,Han Y,et al.PARK2 suppresses the proliferation of high-grade serous ovarian carcinoma via inducing the proteasomal degradation of ZNF703[J].Med Oncol,2024,41(8):207.
[12] Zhang X,Mu X,Huang O,et al.ZNF703 promotes triple-negative breast cancer cells through cell-cycle signaling and associated with poor prognosis[J].BMC Cancer,2022,22(1):226.
[13] Guo J,Luo C,Yang Y,et al.MiR-491-5p,as a tumor suppressor,prevents migration and invasion of breast cancer by targeting ZNF-703 to regulate AKT/mTOR pathway[J].Cancer Manag Res,2021(13):403-413.